MeiraGTx Q2 net loss $20.1M ($0.46/sh); cash runway into Q2 2023

MeiraGTx Holdings plc

2022-Q2 EPS reported -$0.99 revenue$9,711,000

Net loss attributable to shareholders $20.1M ($0.46/sh) vs $25.4M ($0.69/sh) in Q2 2020.
License revenue $5.1M (up from $2.5M); R&D spend $15.2M, G&A $10.4M.
Cash and equivalents $172.6M (down from $194.8M); believes funded into Q2 2023.
Expects to initiate Phase 3 Lumeos trial for XLRP, Phase 3 for AAV-RPE65, and file IND for AAV-GAD in Parkinsons in H2 2021.
Manufacturing facility to support at least six clinical programs in next 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.